Second-line Treatment for Non-Small-Cell Lung Cancer: One Size Does Not Fit All

被引：12

作者：

Caponi, Sara ^{[1
,4
]}

Vasile, Enrico ^{[1
,4
]}

Ginocchi, Laura ^{[1
,4
]}

Tibaldi, Carmelo ^{[3
,4
]}

Borghi, Francesca ^{[1
,4
]}

D'Incecco, Armida ^{[3
,4
]}

Lucchesi, Maurizio ^{[1
,4
]}

Caparello, Chiara ^{[1
,4
]}

Andreuccetti, Michele ^{[1
,4
]}

Falcone, Alfredo ^{[1
,2
,4
]}

机构：

[1] Azienda Osped Univ Pisana, UO Oncol Univ 2, Polo Oncol Area Vasta Nord Ovest, Ist Toscano Tumori, I-56126 Pisa, Italy

[2] Univ Pisa, Dipartimento Oncol Trapianti & Nuove Tecnol Med, I-56100 Pisa, Italy

[3] Ist Toscano Tumori, Azienda USL Livorno 6, UO Oncol Med, Tumori, Italy

[4] Azienda Osped Univ Pisana & Azienda USL 6 Livorno, Dipartimento Interaziendale Oncol Med, Pisa, Italy

来源：

CLINICAL LUNG CANCER | 2010年 / 11卷 / 05期

关键词：

Docetaxel; Epidermal growth factor receptor; Pemetrexed; Tyrosine kinase inhibitors; RANDOMIZED PHASE-III; CISPLATIN PLUS GEMCITABINE; GROWTH-FACTOR RECEPTOR; EVERY; WEEKS; WEEKLY DOCETAXEL; COMBINATION CHEMOTHERAPY; SUPPORTIVE CARE; VS; DOCETAXEL; STAGE-IIIB; OPEN-LABEL;

D O I：

10.3816/CLC.2010.n.040

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

After progression following first-line treatment, many patients with advanced non-small-cell lung cancer (NSCLC) still have a good performance status and can be considered for further treatments. Based on 2 randomized phase III trials, docetaxel was the first approved second-line therapy associated with longer survival and better quality of life compared with best supportive care alone and vinorelbine or ifosfamide. Since then, other agents have been approved for the second-line treatment of NSCLC (ie, pemetrexed, erlotinib, and gefitinib). Recently, new molecular-targeted agents are being increasingly considered in this setting, above all, bevacizumab and vandetanib. The discovery and validation of predictive markers of efficacy for both chemotherapy drugs and the new targeted therapies is of primary importance for the selection of second-line treatment for all patients with advanced NSCLC.

引用

页码：320 / 327

页数：8

共 62 条

[41] Global cancer statistics, 2002 [J].

Parkin, DM ;

Bray, F ;

Ferlay, J ;

Pisani, P .

CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (02) :74-108

[42] Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer [J].

Paz-Ares, L. ;

Ross, H. ;

O'Brien, M. ;

Riviere, A. ;

Gatzemeier, U. ;

Von Pawel, J. ;

Kaukel, E. ;

Freitag, L. ;

Digel, W. ;

Bischoff, H. ;

Garcia-Campelo, R. ;

Iannotti, N. ;

Reiterer, P. ;

Bover, I. ;

Prendiville, J. ;

Eisenfeld, A. J. ;

Oldham, F. B. ;

Bandstra, B. ;

Singer, J. W. ;

Bonomi, P. .

BRITISH JOURNAL OF CANCER, 2008, 98 (10) :1608-1613

[43] Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial [J].

Pectasides, D ;

Pectasides, M ;

Farmakis, D ;

Kostopoulou, V ;

Nikolaou, M ;

Gaglia, A ;

Koumpou, M ;

Mylonakis, N ;

Xiros, N ;

Economopoulos, T ;

Raptis, SA .

ANNALS OF ONCOLOGY, 2005, 16 (02) :294-299

[44]

Peterson P., 2007, Journal of Thoracic Oncology, V2, pS851

[45] American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003 [J].

Pfister, DG ;

Johnson, DH ;

Azzoli, CG ;

Sause, W ;

Smith, TJ ;

Baker, S ;

Olak, J ;

Stover, D ;

Strawn, JR ;

Turrisi, AT ;

Somerfield, MR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :330-353

[46] Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial [J].

Pirker, Robert ;

Pereira, Jose R. ;

Szczesna, Aleksandra ;

von Pawel, Joachim ;

Krzakowski, Maciej ;

Ramlau, Rodryg ;

Vynnychenko, Ihor ;

Park, Keunchil ;

Yu, Chih-Teng ;

Ganul, Valentyn ;

Roh, Jae-Kyung ;

Bajetta, Emilio ;

O'Byrne, Kenneth ;

de Marinis, Filippo ;

Eberhardt, Wilfried ;

Goddemeier, Thomas ;

Emig, Michael ;

Gatzemeier, Ulrich ;

Pirker, R. ;

Thatcher, N. ;

Armand, J. P. ;

Camus, P. ;

Victor, N. ;

Emig, M. ;

Mueser, M. ;

Pilz, K. ;

Goddemeier, T. ;

Montaner, I. ;

Lachs, Martin ;

Hoang-Sayag, Loan ;

Alvarez, A. ;

Coppola, F. ;

Recondo, G. ;

Richardet, E. ;

Kirsten, F. ;

Karapetis, C. ;

Parente, P. ;

Michael, M. ;

White, S. ;

Boyce, A. ;

Lewis, C. ;

Slancar, M. ;

Pavlakis, N. ;

Abdi, E. ;

Underhill, C. ;

Pittman, K. ;

Burghuber, O. ;

Pirker, R. ;

Ruckser, R. ;

Ulsperger, E. .

LANCET, 2009, 373 (9674) :1525-1531

[47] Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer [J].

Ramlau, R ;

Gervais, R ;

Krzakowski, M ;

Von Pawel, J ;

Kaukel, E ;

Abratt, RP ;

Dharan, B ;

Grotzinger, KM ;

Ross, G ;

Dane, G ;

Shepherd, FA .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2800-2807

[48] Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL [J].

Reck, Martin ;

von Pawel, Joachim ;

Zatloukal, Petr ;

Ramlau, Rodryg ;

Gorbounova, Vera ;

Hirsh, Vera ;

Leighl, Natasha ;

Mezger, Joerg ;

Archer, Venice ;

Moore, Nicola ;

Manegold, Christian .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1227-1234

[49] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].

Sandler, Alan ;

Gray, Robert ;

Perry, Michael C. ;

Brahmer, Julie ;

Schiller, Joan H. ;

Dowlati, Afshin ;

Lilenbaum, Rogerio ;

Johnson, David H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550

[50] The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies [J].

Scagliotti, Giorgio ;

Hanna, Nasser ;

Fossella, Frank ;

Sugarman, Katherine ;

Blatter, Johannes ;

Peterson, Patrick ;

Simms, Lorinda ;

Shepherd, Frances A. .

ONCOLOGIST, 2009, 14 (03) :253-263

← 1 2 3 4 5 6 7 →